Assessment of the Prognostic and Treatment-Predictive Performance of the Combined HOXB13:IL17BR-MGI Gene Expression Signature in the Trans-ATAC Cohort

Abstract

We compared the prognostic ability of the Breast Cancer Index (BCI), Oncotype DX Recurrence Score (RS) and IHC4 for both early and late recurrence among patients with ER+, node negative (N0) disease with the ATAC clinical trial. BCI was performed from 1102 primary tumor samples from ER+ patients were evaluated. BCI-L, IHC4 and RS had significant prognostic performance for early DR (BCO-L, p<0-0002), while only BCI-L was significant for late DR (LR- X2: 7-97, p=0- 0048). For risk of early DR at 5 years, BCI-L classified 59%, 25%, and 16% of patients with 1.3%, 5.6%, and 18.1% for low, intermediate and high risk, respectively. For risk of late DR at 10 years, BCI-L classified 61%, 25%, and 14% of patients.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2013
Accession Number
ADA598880

Entities

People

  • Dennis Sgroi

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Breast Cancer
  • Clinical Trials
  • Data Analysis
  • Diseases And Disorders
  • Estrogens
  • Gene Expression
  • Health Services
  • Information Systems
  • Lymph Nodes
  • Medical Personnel
  • Multivariate Analysis
  • Neoplasms
  • Oncology
  • Pcr Testing
  • Statistical Analysis
  • Therapy

Fields of Study

  • Medicine

Readers

  • Aerospace Research.
  • Oncology and Biomarker-Based Cancer Detection.